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Sweet\'s syndrome is an acute febrile neutrophilic dermatosis characterized by neutrophilic erythema and fever \[[@B1]\]. The diagnosis of Sweet\'s syndrome is established by the presence of 2 major and at least 2 minor criteria. Major criteria include: (1) the abrupt onset of painful erythematous plaques or nodules, occasionally with vesicles, pustules, or bullae; and (2) neutrophilic infiltrates in the dermis without leukocytoclastic vasculitis. Minor criteria include: (1) a preceding nonspecific respiratory or gastrointestinal tract infection or vaccination, or an association with inflammatory disease, hemoproliferative disorder, solid malignant tumor, or pregnancy; (2) constitutional symptoms and fever; (3) leukocytosis; and (4) excellent response to treatment with systemic corticosteroids \[[@B2]\].

Cytokines play an etiologic role, directly and/or indirectly, in the development of Sweet\'s syndrome \[[@B3]\]. Granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor, interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α are potential cytokine candidates \[[@B4], [@B5]\]. Particularly, serum G-CSF levels have been reported to be significantly higher in patients with active Sweet\'s syndrome compared to that in patients with inactive status \[[@B4]\].

Systemic corticosteroids, colchicine, and potassium iodide are first-line treatment options for Sweet\'s syndrome \[[@B6]\]. Second-line therapies include nonsteroidal anti-inflammatory drugs, dapsone, clofazimine, cyclosporine, and thalidomide. However, this disease may recur following either spontaneous remission or therapy-induced clinical resolution. The efficacy of rituximab \[[@B1]\], anti-TNF-α agents \[[@B7]\], and IL-1 receptor antagonists \[[@B8], [@B9]\] has been reported in refractory Sweet\'s syndrome. However, these agents sometimes cause adverse effects including serious infections, interstitial pneumonitis, and liver dysfunction. Although granulocyte and monocyte adsorption apheresis (GMA) therapy has significant efficacy with no safety concerns in pustular psoriasis \[[@B10], [@B11]\], ulcerative colitis \[[@B12]\], and pyoderma gangrenosum \[[@B13]\], its efficacy in Sweet\'s syndrome has only been reported in 1 case \[[@B14]\]. GMA is an extracorporeal apheresis that removes activated granulocytes and monocytes using a column packed with cellulose acetate beads (Adacolumn; JIMRO, Takasaki, Japan) \[[@B12]\]. Herein, we present the successful treatment of a patient with recurrent Sweet\'s syndrome by GMA therapy, which was associated with the restoration of elevated serum G-CSF level.

Case Report {#sec1_2}
===========

A 55-year-old Japanese woman with an underlying atopic dermatitis since childhood exhibited edema and erythematous lesions with pain on her four extremities, trunk, and neck (Fig. [1a](#f1){ref-type="fig"}). She also had a fever (body temperature \>39°C). Laboratory findings were as follows: leukocyte count, 13,700/μL (86.5% of neutrophils); C-reactive protein (CRP), 7.27 mg/dL; and serum albumin, 3.5 g/dL. Other laboratory data were within normal ranges. Histological findings from the erythema on the right thigh revealed remarkable neutrophil infiltration in the dermis and subcutaneous tissue without leukocytoclastic vasculitis (Fig. [1b, c](#f1){ref-type="fig"}). From these findings, the patient was diagnosed with Sweet\'s syndrome \[[@B2]\]. Oral administration of prednisolone (PSL) at 0.6 mg/kg/day was effective; thus, the dose was gradually tapered. However, the same symptoms recurred after 3 months, and further recurred 6 times within 2 years. At each recurrence, she was treated with 0.6 mg/kg/day of PSL. Although PSL 0.15--0.3 mg/kg/day was continued for the next 3 years as a maintenance dose, the symptoms recurred 5 more times. Nonsteroidal anti-inflammatory drugs were ineffective, and colchicine was discontinued due to adverse effects such as nausea and headache. Preceding triggers such as infection, malignancy, or drugs could not be identified. PSL was discontinued 7 years after the initial onset, and blood tests were performed periodically every 2--3 months.

She visited us again due to multiple exudative erythema with pain on the trunk and upper extremities with fever (\>39°C) lasting for 7 days. Laboratory findings were as follows: leukocyte count, 9,960/μL (84.8% of neutrophils); CRP, 6.65 mg/dL; serum amyloid A protein (SAA), 725 μg/mL (normal \<8.0 μg/mL); and G-CSF 297 pg/mL (normal \<39 pg/mL). She was diagnosed with a recurrence of Sweet\'s syndrome, and was treated with GMA therapy once a week for 3 consecutive weeks without any other treatments. The day after the first session of GMA therapy, all symptoms including erythema and fever were completely resolved. After 1 week, serum G-CSF level was significantly reduced to \<0.19 pg/mL. Leukocyte count, neutrophil count, and serum SAA and CRP levels were also reduced, and were restored within normal ranges by 2 weeks (Fig. [2](#f2){ref-type="fig"}). The symptoms have not appeared for at least 4 months without oral administration of PSL.

Discussion {#sec1_3}
==========

Innate immune disorders include: (1) autoinflammatory diseases such as deficiency of IL-36 receptor antagonist (DITRA), pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome (PASH), and familial Mediterranean fever; and (2) neutrophilic diseases such as Sweet\'s syndrome and pyoderma gangrenosum \[[@B15]\]. Although both types of disease are described as distinct, they show many overlapping clinical, pathogenetic, histological, and genetic features \[[@B15]\]. Mutations in *MEFV*, an autoinflammatory gene, have been identified in some cases of Sweet\'s syndrome \[[@B16]\]. GMA therapy has shown efficacy in several autoinflammatory and neutrophilic diseases such as PASH syndrome \[[@B17]\], DITRA (pustular psoriasis) \[[@B18]\], palmoplantar pustulosis \[[@B19]\], and Behçet\'s disease \[[@B20]\]. Although the efficacy of GMA therapy in Sweet\'s syndrome has been reported in 1 patient \[[@B14]\], it has not been fully described. In the present case, GMA therapy resulted in a rapid and significant response with reduced clinical symptoms and restoration of abnormal laboratory findings, similar to that reported in patients with the above diseases.

Sweet\'s syndrome presents in several clinical settings: classical (or idiopathic), malignancy-associated (including leukemia), and drug-induced. It is also well known to be associated with autoimmune diseases such as Sjögren\'s syndrome and rheumatoid arthritis, and inflammatory bowel diseases such as ulcerative colitis and Crohn\'s disease \[[@B6]\]. The administration of G-CSF is responsible for the majority of cases with drug-induced Sweet\'s syndrome \[[@B6]\]. The present case had no associated diseases except for atopic dermatitis. Although she had not been administered G-CSF, her serum G-CSF level was elevated during the active phase of the recurrent Sweet\'s syndrome. The elevated G-CSF level dropped in response to GMA therapy (Fig. [2](#f2){ref-type="fig"}), indicating that high levels of G-CSF may be a useful indicator of activity in Sweet\'s syndrome. In addition, G-CSF-induced suppression of neutrophil apoptosis appears to be deeply involved in the pathogenesis of Sweet\'s syndrome \[[@B4]\]. Dysregulation of neutrophil homeostasis results in excessive inflammation and subsequent tissue damage. These findings support the hypothesis that activated granulocyte and monocytes play a major role in the immunopathogenesis of Sweet\'s syndrome, and the removal of these cells by GMA therapy is an expedient mechanism-based therapy. Clinical studies are needed to fully evaluate the efficacy and safety of GMA for refractory Sweet\'s syndrome.
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![**a** Clinical features on the patient\'s back at the first visit. Histopathological findings of a biopsy specimen from erythema (hematoxylin-eosin) (original magnification ×40; **b**) (original magnification ×200; **c**).](cde-0009-0013-g01){#f1}
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